Without an IPO, Rib-X Raises $67.5 Million In Venture Funding
This article was originally published in The Pink Sheet Daily
Executive Summary
Rib-X will use the venture infusion to try to replicate Phase IIb data that indicated superiority to vancomycin for its broad-spectrum fluoroquinolone antibiotic.
You may also be interested in...
Re-Named Melinta Moving Ahead With Delafloxacin And Novel Class Of Antibiotics
Formerly known as Rib-X Pharmaceuticals, Connecticut biotech reacquires rights to RX-04 antibiotic platform from Sanofi and moves forward with venture backing from Vatera and new management team.
Antibiotic Market Snapshot: In Exchange For Higher Prices, More Value
Drug developers face enormous regulatory and commercial hurdles in the antibiotics market, but industry is looking to challenge the current business model with new premium-priced drugs that deliver compelling pharmaco-economic benefits over generics.
The Future Of Private Biotech Investment: A Q&A With Jonathan Leff
Long-time Warburg Pincus investor Jonathan Leff is making a move to Deerfield Management. He tells “The Pink Sheet” about his plans and contemplates what’s next for investment in private biotechs.